John A. Double

3.0k total citations
75 papers, 2.5k citations indexed

About

John A. Double is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, John A. Double has authored 75 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 27 papers in Oncology and 20 papers in Organic Chemistry. Recurrent topics in John A. Double's work include Cancer therapeutics and mechanisms (10 papers), Synthesis and biological activity (9 papers) and Pharmacogenetics and Drug Metabolism (8 papers). John A. Double is often cited by papers focused on Cancer therapeutics and mechanisms (10 papers), Synthesis and biological activity (9 papers) and Pharmacogenetics and Drug Metabolism (8 papers). John A. Double collaborates with scholars based in United Kingdom, Ireland and Netherlands. John A. Double's co-authors include Angelika M. Burger, M C Bibby, Michael J. Moore, Christoph Schultes, Fangping Dai, Stephen Neidle, Anthony P. Reszka, Roger M. Phillips, Michael C. Bibby and A. M. Burger and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer and Cancer Research.

In The Last Decade

John A. Double

74 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John A. Double United Kingdom 25 1.7k 423 376 358 278 75 2.5k
Jeffrey C. Boehm United States 19 1.8k 1.1× 648 1.5× 923 2.5× 239 0.7× 177 0.6× 35 2.9k
Mamoru Shoji United States 30 1.8k 1.1× 493 1.2× 371 1.0× 360 1.0× 119 0.4× 63 3.0k
Xianzhang Bu China 31 2.0k 1.2× 601 1.4× 608 1.6× 560 1.6× 148 0.5× 103 3.3k
Thomas Robert France 27 1.1k 0.7× 330 0.8× 472 1.3× 343 1.0× 85 0.3× 98 2.5k
Tomoko Oh‐hara Japan 31 2.0k 1.2× 1.7k 4.1× 237 0.6× 364 1.0× 184 0.7× 65 3.4k
Michael C. Bibby United Kingdom 20 778 0.5× 389 0.9× 291 0.8× 300 0.8× 81 0.3× 47 1.7k
Andrzej Składanowski Poland 27 2.1k 1.3× 1.1k 2.5× 548 1.5× 212 0.6× 98 0.4× 62 2.9k
Chunyong Ding China 31 1.8k 1.1× 406 1.0× 576 1.5× 209 0.6× 125 0.4× 110 3.1k
Michael I. Walton United Kingdom 28 1.7k 1.1× 719 1.7× 308 0.8× 442 1.2× 36 0.1× 49 2.5k
Asher Begleiter Canada 31 1.5k 0.9× 496 1.2× 494 1.3× 191 0.5× 82 0.3× 99 2.5k

Countries citing papers authored by John A. Double

Since Specialization
Citations

This map shows the geographic impact of John A. Double's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Double with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Double more than expected).

Fields of papers citing papers by John A. Double

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Double. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Double. The network helps show where John A. Double may publish in the future.

Co-authorship network of co-authors of John A. Double

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Double. A scholar is included among the top collaborators of John A. Double based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Double. John A. Double is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicolaou, Anna, et al.. (2006). Methionine dependence of tumours: A biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. Biochemical Pharmacology. 71(6). 772–778. 19 indexed citations
2.
Double, John A.. (2004). A Pharmacological Approach for the Selection of Potential Anticancer Agents. Alternatives to Laboratory Animals. 32(2_suppl). 41–48. 4 indexed citations
3.
Gibson, Paul, Jason H. Gill, Jill M. Seargent, et al.. (2003). Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development.. Bradford Scholars (University of Bradford). 2(6). 527–34. 80 indexed citations
4.
Double, John A. & Michael J. Thompson. (2002). Telomeres and telomerase : methods and protocols. Humana Press eBooks. 7 indexed citations
5.
6.
Double, John A., et al.. (2001). A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. British Journal of Cancer. 85(8). 1137–1146. 47 indexed citations
7.
Ruparelia, Ketan C., L H Patterson, S. R. McKeown, et al.. (2000). True. British Journal of Cancer. 82(12). 1984–1990. 65 indexed citations
8.
Aitken, R. A., et al.. (1997). Synthesis and Antitumour Activity of New Derivatives of Flavone‐8‐acetic Acid (FAA). Part 2: Ring‐Substituted Derivatives. Archiv der Pharmazie. 330(7). 215–224. 8 indexed citations
9.
Uchegbu, Ijeoma F., John A. Double, Lloyd R. Kèlland, John A. Turton, & Alexander T. Florence. (1996). The Activity of Doxorubicin Niosomes Against an Ovarian Cancer Cell Line and Threein VivoMouse Tumour Models. Journal of drug targeting. 3(5). 399–409. 41 indexed citations
10.
11.
Bibby, Michael C., et al.. (1993). Potentiation of EO9 anti-tumour activity by hydralazine. European Journal of Cancer. 29(7). 1033–1035. 16 indexed citations
12.
Hendriks, Hans R., Dan Berger, M.C. Bibby, et al.. (1993). EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. European Journal of Cancer. 29(6). 897–906. 89 indexed citations
13.
Walton, Michael I., Michael C. Bibby, John A. Double, Jane A. Plumb, & Paul Workman. (1992). DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. European Journal of Cancer. 28(10). 1597–1600. 48 indexed citations
14.
Double, John A., M.C. Bibby, Paul M. Loadman, & J. C. Bloomer. (1988). Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations. European Journal of Cancer and Clinical Oncology. 24(8). 1355–1360. 4 indexed citations
15.
Phillips, Roger M., M.C. Bibby, & John A. Double. (1988). In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation. European Journal of Cancer and Clinical Oncology. 24(8). 1365–1371. 5 indexed citations
16.
Phillips, Roger M., M.C. Bibby, & John A. Double. (1988). Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemotherapy and Pharmacology. 21(2). 168–72. 16 indexed citations
17.
Bibby, M C & John A. Double. (1986). Activity of N-[N?-(2-chloroethyl)-N?-nitrosocarbamoyl]-alanine and derivatives against transplantable adenocarcinomata of the mouse colon (MAC). Journal of Cancer Research and Clinical Oncology. 112(1). 47–49. 4 indexed citations
18.
Workman, Paul, C.R. Ball, & John A. Double. (1976). Enzyme activated anti-tumour agents— II. The role of alkaline phosphatase in the release of p-hydroxyaniline mustard from its phosphate conjugate in cells in culture. Biochemical Pharmacology. 25(10). 1139–1144. 8 indexed citations
19.
Berenbaum, M. C., et al.. (1973). The effect of microsomal enzyme inhibition on the immunosuppressive and toxic effects of cyclophosphamide.. PubMed. 14(2). 257–70. 16 indexed citations
20.
Connors, T.A. & John A. Double. (1970). Alkylation of the dna of sensitive and resistant tumours by a nitrogen mustard derivative. International Journal of Cancer. 5(3). 375–383. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey C. Boehm Breakdown of academic impact, for papers by Mamoru Shoji Breakdown of academic impact, for papers by Xianzhang Bu Breakdown of academic impact, for papers by Thomas Robert Breakdown of academic impact, for papers by Tomoko Oh‐hara Breakdown of academic impact, for papers by Michael C. Bibby Breakdown of academic impact, for papers by Andrzej Składanowski Breakdown of academic impact, for papers by Chunyong Ding Breakdown of academic impact, for papers by Michael I. Walton Breakdown of academic impact, for papers by Asher Begleiter
Rankless by CCL
2026